Companies › Tourmaline Bio, Inc., a Novartis Company
1 active drug program in 1 registered trial: 1 Phase 2; Ophthalmology; next expected readout Sep 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Pacibekitug (TOUR006) Interleukin-6 inhibitor | IL6 | Phase 2 | Thyroid Eye Disease | Sep 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06088979 | Pacibekitug (TOUR006) | Phase 2 | Thyroid Eye Disease | Ophthalmology | Sep 2027 |
Vantage Biosciences Sunhawk Vision Biotech Qingdao WanMing BioCell Pharmaceutics Caravel Oculus Tavo Biotherapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.